Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
調査の概要
詳細な説明
One of the problems in managing adrenocortical tumors is the ability to distinguish between benign and malignant tumors, while needle biopsy is unable to distinguish between the two situations. Therefore, when imaging tests demonstrate a suspected malignant adrenal tumor, surgical excision of the tumor is needed. Usually, the histological WIESS criteria are used in order to determine malignancy. However, there are cases when adrenal tumors were defined by WIESS criteria as benign but metastasized later. Moreover, there is no reliable test than can determine prognosis. KI-67 labeling index is a proliferation biomarker which is used to tell more about the malignant potential and prognosis of adrenal carcinoma.
In various types of tumors, proliferation biomarkers are used in attempt to tell about prognosis. In this study, the investigators will examine whether some biomarkers can differentiate between adrenal carcinoma and adenoma and if the degree of expression of these markers is correlated with prognosis.
The investigators will retrospectively collect 30 cases of adrenal carcinoma, 30 cases of adrenal adenoma and 10 cases of normal adrenals. All specimens are preserved with formalin. The investigators will re-review the WIESS criteria and all samples will be analyzed for the index labeling of the following proliferation biomarkers: MCM3, MCM2, KI-67, P53, NEUROPILIN -1, METALLOTHIONEIN, SEMAPHORIN-3A. The investigators will examine if there is any correlation between the labeling index of each biomarker, WIESS criteria and prognosis of the tumor.
研究の種類
入学 (予想される)
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- adrenal carcinoma
- adrenal adenoma
- normal adrenal tissue
Exclusion Criteria:
- NA
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
MCM3 expression
時間枠:1 year
|
Difference in MCM3 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
MCM2 expression
時間枠:1 year
|
Difference in MCM2 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
P53 expression
時間枠:1 year
|
Difference in P53 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
NEUROPILIN -1 expression
時間枠:1 year
|
Difference in NEUROPILIN -1 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
METALLOTHIONEIN expression
時間枠:1 year
|
Difference in METALLOTHIONEIN labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
SEMAPHORIN-3A expression
時間枠:1 year
|
Difference in SEMAPHORIN-3A labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
E-caderein expression
時間枠:1 year
|
Difference in E-caderein labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
KI67
時間枠:1 year
|
Difference in Ki67 labeling index between adrenal cortical adenoma versus adrenocortical carcinoma
|
1 year
|
Prognosis
時間枠:1 year
|
Correlation between the labeling index of each biomarker, WIESS criteria and prognosis of the tumor.
|
1 year
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。